Valneva (NASDAQ:VALN) Trading 6.2% Higher – Here’s Why

Valneva SE (NASDAQ:VALN)’s share price rose 6.2% during mid-day trading on Monday . The company traded as high as $6.16 and last traded at $6.35. Approximately 13,553 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 26,764 shares. The stock had previously closed at $5.98.

Wall Street Analyst Weigh In

VALN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Valneva in a report on Wednesday. Guggenheim reduced their price objective on Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, March 24th.

Valneva Stock Performance

The company has a 50 day moving average price of $6.90 and a 200-day moving average price of $5.61. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $550.14 million, a P/E ratio of -52.08 and a beta of 1.85.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Equities analysts expect that Valneva SE will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. ABC Arbitrage SA acquired a new position in Valneva during the fourth quarter valued at $84,000. GAMMA Investing LLC purchased a new stake in shares of Valneva in the first quarter worth approximately $94,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.